What is Exdensur? A new FDA-approved asthma biologic from GSK that only needs two doses a year for severe eosinophilic asthma ...
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...
The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist (LAMA) or a Leukotriene Receptor Antagonist (LTRA) on top of a moderate-dose ...
A 21-year-old engineering student from Delhi, suffering from severe allergic asthma and rashes, successfully underwent personalised treatment in Hyderabad. Combining immunotherapy, probiotics and ...
The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...
Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...
US regulators have approved GSK’s Exdensur treatment for severe asthma with an eosinophilic phenotype, marking the first ...
Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...
The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback